{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:17:42Z","timestamp":1783696662306,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clgc.2020.12.008","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T20:02:34Z","timestamp":1610222554000},"page":"e171-e177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-9018","authenticated-orcid":false,"given":"Fernando C.","family":"Maluf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabr\u00edcio A.M.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro E.R.","family":"Liedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Brust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina G.","family":"Inoc\u00eancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando S.M.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-2616","authenticated-orcid":false,"given":"Oren","family":"Smaletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1936-2605","authenticated-orcid":false,"given":"Daniel I.","family":"Cubero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2020.12.008_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2020.12.008_bib2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clgc.2020.12.008_bib3","doi-asserted-by":"crossref","first-page":"i4405","DOI":"10.1136\/bmj.i4405","article-title":"Advances in the management of castration resistant prostate cancer","volume":"355","author":"Ritch","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2020.12.008_bib4","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2020.12.008_bib5","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3109\/0284186X.2013.770164","article-title":"Population-based study on use of chemotherapy in men with castration resistant prostate cancer","volume":"52","author":"Lissbrant","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2020.12.008_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2020.12.008_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.12.008_bib8","first-page":"1444","article-title":"Castration-resistant prostate cancer: AUA Guideline Amendment 2015","volume":"195","author":"Lowrance","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.12.008_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2020.12.008_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A\u00a0multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2020.12.008_bib11","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2020.12.008_bib12","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cncr.22205","article-title":"Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions","volume":"107","author":"Leibovici","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2020.12.008_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1006\/gyno.1997.4630","article-title":"Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial","volume":"65","author":"Carlson","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clgc.2020.12.008_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-016-4028-0","article-title":"Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review","volume":"161","author":"Fernandes","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clgc.2020.12.008_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/tbj.12501","article-title":"Clinical outcomes and cost-effectiveness of primary prophylaxis of febrile neutropenia during adjuvant docetaxel and cyclophosphamide chemotherapy for breast cancer","volume":"21","author":"Yu","year":"2015","journal-title":"Breast J"},{"key":"10.1016\/j.clgc.2020.12.008_bib16","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S1470-2045(17)30605-8","volume":"18","author":"Beer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2020.12.008_bib17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/14740338.2014.939583","article-title":"Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program","volume":"13","author":"Castellano","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clgc.2020.12.008_bib18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.eururo.2012.08.058","article-title":"Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme","volume":"63","author":"Heidenreich","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.12.008_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000441379","article-title":"Translating clinical evidence-based medicine into the real world: single-center experience with cabazitaxel in metastatic prostate cancer patients","volume":"61","author":"Moriceau","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clgc.2020.12.008_bib20","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.12.008_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5489\/cuaj.3470","article-title":"Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone","volume":"10","author":"Saad","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2020.12.008_bib22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bju.13069","article-title":"Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)","volume":"116","author":"Bahl","year":"2015","journal-title":"BJU Int"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:18Z","timestamp":1761564858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1558767321000082"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2020.12.008","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}